Jeremy J. Pappacena

Statistics

Publications

Citations

107

H-Index

Active since

2018

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

Allegheny Health Network

Jeremy J. Pappacena is an author at Memorial Sloan Kettering Cancer Center specializing in tyrosine kinase inhibitor therapy, medicine, and tyrosine kinase inhibitors.

Publications per year

2018–2020

Publications

Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia

Amber C. King, Jeremy J. Pappacena, Martin S. Tallman et al. · Leukemia Research · 2019 · 64 citations · Full text

Medicine, Hematology, Oncology +13

Drug interactions with Bruton’s tyrosine kinase inhibitors: clinical implications and management

Karen Fancher, Jeremy J. Pappacena · Cancer Chemotherapy and Pharmacology · 2020 · 18 citations

Medicine, Pharmacology, Pharmacotherapy +17

Tolerability and toxicity of pegaspargase in adults 40 years and older with acute lymphoblastic leukemia

Ryan J. Daley, Sridevi Rajeeve, Charlene Kabel et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2020 · 13 citations

Pharmacy, Pharmacology, Pharmacotherapy +14

Blinatumomab Administered Concurrently with Oral Tyrosine Kinase Inhibitor Therapy Is a Well-Tolerated Consolidation Strategy and Eradicates Measurable Residual Disease in Adults with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Amber C. King, Jeremy J. Pappacena, Martin S. Tallman et al. · Blood · 2018 · 12 citations

Medicine, Hematology, Oncology +13

1–4 of 4